Astria Therapeutics (ATXS) News Today $5.36 +0.20 (+3.88%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$5.34 -0.02 (-0.28%) As of 05/2/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cantor Fitzgerald Comments on ATXS FY2025 EarningsAstria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Astria Therapeutics in a research note issued to investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the biotechnology compaMay 3 at 8:12 AM | marketbeat.comCantor Fitzgerald Predicts ATXS FY2025 EarningsMay 3 at 3:09 AM | americanbankingnews.comAstria Therapeutics (ATXS) to Release Quarterly Earnings on ThursdayAstria Therapeutics (NASDAQ:ATXS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-catabasis-pharmaceuticals-inc-stock/)May 3 at 3:08 AM | marketbeat.comAstria Therapeutics reports progress in HAE drug trialMay 2 at 8:48 PM | investing.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2 at 4:10 PM | businesswire.comAstria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Cantor FitzgeraldCantor Fitzgerald upgraded Astria Therapeutics to a "strong-buy" rating in a research note on Tuesday.May 2 at 7:50 AM | marketbeat.comAstria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & ImmunologyMay 1 at 9:09 AM | finance.yahoo.comAdage Capital Partners GP L.L.C. Sells 54,743 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Adage Capital Partners GP L.L.C. lowered its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 7.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 713,200 shares of the biotechnology company's stock aftMay 1 at 5:30 AM | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Rating Increased to Strong-Buy at Cantor FitzgeraldMay 1 at 1:39 AM | americanbankingnews.comCantor Fitzgerald Initiates Coverage of Astria Therapeutics (ATXS) with Overweight RecommendationApril 30, 2025 | msn.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of "Buy" by BrokeragesAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and two have assigned a strongApril 25, 2025 | marketbeat.comRaymond James Financial Inc. Takes $707,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)Raymond James Financial Inc. purchased a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 79April 7, 2025 | marketbeat.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | businesswire.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of "Buy" from BrokeragesAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has earned a consensus rating of "Buy" from the seven ratings firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendaMarch 30, 2025 | marketbeat.comLifesci Capital Issues Negative Estimate for ATXS EarningsAstria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Equities researchers at Lifesci Capital decreased their FY2025 earnings per share estimates for Astria Therapeutics in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky now expects that the biotechnology cMarch 15, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for ATXS Q1 Earnings?Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Astria Therapeutics in a research report issued on Tuesday, March 11th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earningMarch 15, 2025 | marketbeat.comWedbush Reduces Earnings Estimates for Astria TherapeuticsAstria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Equities researchers at Wedbush dropped their Q1 2025 earnings estimates for shares of Astria Therapeutics in a note issued to investors on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the biotechnology company will pMarch 15, 2025 | marketbeat.comAstria Therapeutics price target raised to $28 from $27 at WedbushMarch 12, 2025 | markets.businessinsider.comAstria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday.March 12, 2025 | marketbeat.comWedbush Keeps Their Buy Rating on Astria Therapeutics (ATXS)March 12, 2025 | markets.businessinsider.comAstria Therapeutics (ATXS) Gets a Buy from WedbushMarch 12, 2025 | markets.businessinsider.comAstria Therapeutics (NASDAQ:ATXS) Announces Quarterly Earnings ResultsAstria Therapeutics (NASDAQ:ATXS - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01.March 12, 2025 | marketbeat.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | businesswire.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Buy" from AnalystsShares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have earned a consensus rating of "Buy" from the eight brokerages that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the companMarch 4, 2025 | marketbeat.comTD Cowen Remains a Buy on Astria Therapeutics (ATXS)March 1, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS)HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Thursday.February 28, 2025 | marketbeat.comAstria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary AngioedemaFebruary 27, 2025 | businesswire.comAstria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | finance.yahoo.comAstria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | businesswire.comAstria Therapeutics (ATXS) to Release Earnings on MondayAstria Therapeutics (NASDAQ:ATXS) will be releasing earnings before the market opens on Monday, March 3.February 24, 2025 | marketbeat.comCalculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)February 22, 2025 | finance.yahoo.comAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint CongressFebruary 20, 2025 | finance.yahoo.comAstria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average - What's Next?Astria Therapeutics (NASDAQ:ATXS) Stock Passes Below 50 Day Moving Average - Time to Sell?February 18, 2025 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of "Buy" from AnalystsAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given a consensus rating of "Buy" by the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating onFebruary 7, 2025 | marketbeat.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | businesswire.comAstria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | finance.yahoo.comAstria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific SessionFebruary 4, 2025 | finance.yahoo.comAstria Therapeutics (NASDAQ:ATXS) Upgraded by Citizens Jmp to Strong-Buy RatingCitizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a report on Friday.February 1, 2025 | marketbeat.comAstria Therapeutics initiated with an Outperform at JMP SecuritiesFebruary 1, 2025 | markets.businessinsider.comJMP Securities starts Astria Therapeutics stock at Market OutperformFebruary 1, 2025 | msn.comJMP Securities Initiates Coverage of Astria Therapeutics (ATXS) with Market Outperform RecommendationFebruary 1, 2025 | msn.comAstria Therapeutics (NASDAQ:ATXS) Earns Outperform Rating from Analysts at JMP SecuritiesJMP Securities began coverage on shares of Astria Therapeutics in a research report on Friday. They issued an "outperform" rating and a $26.00 price objective on the stock.January 31, 2025 | marketbeat.comBuy Rating for Astria Therapeutics: Promising Prospects in HAE and Atopic Dermatitis MarketsJanuary 31, 2025 | markets.businessinsider.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 25.7% in JanuaryAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,370,000 shares, an increase of 25.7% from the December 31st total of 2,680,000 shares. Based on an average daily volume of 286,800 shares, the days-to-cover ratio is presently 11.8 days. Approximately 7.4% of the shares of the company are sold short.January 30, 2025 | marketbeat.comAstria initiates Phase 1a Trial of STAR-0310 trial, sees proof of concept in Q3January 24, 2025 | markets.businessinsider.comH.C. Wainwright sets $16 target on Astria Therapeutics stockJanuary 24, 2025 | msn.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short InterestAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 15th total of 2,680,000 shares. Currently, 7.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 286,800 shares, the short-interest ratio is presently 11.8 days.January 16, 2025 | marketbeat.comAstria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAEJanuary 14, 2025 | finance.yahoo.comAstria Therapeutics designs ALPHA-ORBIT Phase 3 trial of navenibart in HAEJanuary 14, 2025 | markets.businessinsider.comOptimistic Buy Rating for Astria Therapeutics Driven by Promising Phase 3 ALPHA-ORBIT TrialJanuary 14, 2025 | markets.businessinsider.com Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXS Media Mentions By Week ATXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATXS News Sentiment▼0.740.58▲Average Medical News Sentiment ATXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATXS Articles This Week▼142▲ATXS Articles Average Week Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 89bio News Today Collegium Pharmaceutical News Today Mineralys Therapeutics News Today Intellia Therapeutics News Today Spyre Therapeutics News Today Zymeworks News Today Arcus Biosciences News Today Nurix Therapeutics News Today Chimerix News Today Avid Bioservices News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATXS) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
